looking like this is the last support channel we have.
Hoping it holds and regains some footing. If not then this will be going below a penny.
Technically it looks perfect for a major reversal.
We need a massive Pr and some Caverstem buy out rumors. (Why they created own LLC for Caverstem)
Holding on tight.
Update from my last analysis.
Price looks to be holding in a wedge formation however I believe the break out is near.
Look for a large extension (around .20 cents) given massive technology adoption, Russia contract plus updated 8-K and Q2 coming soon.
Will update as price continues.
(Picture perfect breakout + retest above)
Couple things to point out;
1B authorized, 189M shares Outstanding.
- Already selling in Indonesia, Turkey, Nigeria, Kenya, Bulgaria
-Plans to begin distribution into China, India, Russia, Poland, Hungry
-USA FDA approval is an 18 month+ project
-Product is superior cancer detection; painless, non-invasive with ...
Good play on a speculative migraine pain management device.
Around 600 M shares outstanding with low float and virtually no debt.
A small investment in $ADHC could yield exponential returns in a few short years.
Market cap could exceed to over $1B+ with successful FDA and clinical studies then successful marketplace execution.
Over $1 PPS is not unreasonable ...
Long term goal north of $3.00 (End 2018- mid 2019)
List of (Possible) events to put this stock into the big leagues and big pharma
1) Flag ship product ATB 436 is now 1 clinical study away from being marketed to the public:
- Antibe was formed to develop safer meds for pain and inflammation with Hydrogen Sulfide tech
- Product ATB 436 was advanced into Phase 2 ...
Q1 Report was very solid however, I believe a retest back down to support is very possible.
On Q1 release price was unable to break new highs causing a double top and suggesting price retracement.
Also FCA is legging on EV tech, which could come to hurt them in 2018.
Perfect head and shoulders formed. Waiting for a small retest @ the neck line then its all down hill from here. Target $150.
Add in global iPhone demand slowing, as well as iPhone X being cancelled and this could sink even further.
Price target .25-.50
Market cap will explode. URA conference coming up at the end of may.
ED procedure already being adopted at big practices with top doctors.
Many more products in the pipeline with massive upside potential in multi billion dollar markets not to mention M&A in big pharma.
Will continue to add.
Long term goal: 1.00
CBD dog drops + treats, as well as pet oral CBD spray.
Q1 over 10M in sales, hoping for more big multi million dollar contracts for this year in this super trendy Marijauna health market.
Extreme upside potential for 2018.
I am looking to hold this OTC stock for a few weeks till the end of the year.
$LDSR is gaining ground before the RSA conference with a new partner announced this week.
$LDSR offers award winning GDPR Compliance, Data Classification and Governance (ClassiDocs product)
As GDPR comes into full effect I suspect many euro and U.S companies will partner with $LDSR. ...